Vident Investment Advisory’s Beam Therapeutics BEAM Stock Holding History

Vident Investment Advisory’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,205	Closed	-$358K	–	122
2023 Q2	$358K	Sell	11,205 -652	-5%	-$21.2K	0.01%	807
2023 Q1	$363K	Buy	11,857 +3,337	+39%	+$132K	0.01%	890
2022 Q4	$333K	Buy	8,520 +343	+4%	+$15.4K	0.01%	850
2022 Q3	$209K	Buy	8,177 +2,629	+47%	+$150K	0.01%	987
2022 Q2	$212K	Buy	5,548 +723	+15%	+$28.7K	0.01%	1113
2022 Q1	$276K	Sell	4,825 -335	-6%	-$22K	0.01%	1090
2021 Q4	$411K	Buy	+5,160	New	+$442K	0.01%	981
2021 Q3	–	Sell	-2,453	Closed	-$316K	–	1162
2021 Q2	$316K	Buy	+2,453	New	+$195K	0.01%	929

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vident Investment Advisory's BEAM Position: Q3 2023 in Review

Vident Investment Advisory sold out of Beam Therapeutics (BEAM) in Q3 2023, closing a stake of 11,205 shares — an estimated $358K sold.

Vident Investment Advisory first reported a position in BEAM in Q2 2021 and held it in 8 quarters. The position peaked at $411K in Q4 2021. 194 funds tracked by Wall St. Rank hold BEAM as of Q3 2023.

Vident Investment Advisory reported no remaining Beam Therapeutics position as of Q3 2023 after selling out during the quarter.
Vident Investment Advisory sold 11,205 Beam Therapeutics shares in Q3 2023, an estimated $358K.
Vident Investment Advisory first reported a position in Beam Therapeutics in Q2 2021 and held it in 8 quarters.
Vident Investment Advisory's Beam Therapeutics position peaked at $411K in Q4 2021.
194 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.